Halozyme Therapeutic (NASDAQ:HALO) shares traded on 2.99% up secure line and closed at $13.44. The stock exchanged hands 2.71 Million shares versus average trading capacity of 1.18 Million shares. It has a market cap of $1.82 Billion.
Wall Street analysts are predicting that Halozyme Therapeutic (NASDAQ:HALO) will report earnings per share of $-0.24 in their quarterly report. For the current quarter Halozyme Therapeutic (NASDAQ:HALO) has high EPS estimates of $-0.22 in contradiction of low EPS estimates of $-0.26. However a year ago for the same quarter the company has reported $-0.21 EPS. Average estimation for the current quarter has been provided by 10 analysts.
Investors as well as the sell-side will be paying close attention to how the actual numbers compare with the estimates. Earnings surprises can have a huge impact on a company’s stock price. Several studies suggest that positive earnings surprises not only lead to an immediate hike in a stock’s price, but also to a gradual increase over time. Hence, it’s not surprising that some companies are known for routinely beating earning projections. A negative earnings surprise will usually result in a decline in share price.
A large surprise factor in either direction typically can lead to a significant swing in the stock price in the hours and days after the report. Previously Halozyme Therapeutic (NASDAQ:HALO) reported $-0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.25 by $-0.01 with surprise factor of -4%.
Halozyme Therapeutic (NASDAQ:HALO) has average revenue estimates of $31.56 Million, compared to low analyst estimates of $29.4 Million and high estimates of $34 Million for the current quarter. A total number of 8 analysts provided estimations over revenues. For the current year the company’s revenue estimates are $130.1 Million compared to low analyst estimates of $124 Million and high estimates of $137.1 Million according to the prediction of 9 analysts.
Taking a broader look at the analyst consensus, according to 10 analysts Halozyme Therapeutic (NASDAQ:HALO)’s price will reach at $16.77 during 52 weeks. Its minimum price target estimates has been figured out at $6.75 while the maximum price target forecast is established at $33.
On the other hand Halozyme Therapeutic (NASDAQ:HALO) has Relative Strength Index (RSI 14) of 58.59 along with Average True Range (ATR 14) of 0.54. Where the relative strength index (RSI) is a technical momentum indicator that compares the magnitude of recent gains to recent losses in an attempt to determine excess buying & selling conditions of an asset, it is one of the most popular technical indicators, computed on the basis of the speed and direction of a stock’s price movement. The RSI value will always move between 0 and 100; the value will be 0 if the stock falls on all 14 days, and 100, if the price moves up on all the days) as suggested by J Welles Wilder. In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. The level of 50 represents neutral market momentum and corresponds with the center line in other oscillators such as MACD (Moving Average Convergence/Divergence). The average true range (ATR) is a measure of volatility introduced by Welles Wilder.
Consequently Halozyme Therapeutic (NASDAQ:HALO)’s weekly and monthly volatility is 3.64%, 3.76% respectively.